Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gabizon

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Medicinal Research Reviews|July 1, 1993
Stability of liposomal doxorubicin formulations: problems and prospectsY Barenholz, S Amselem, D Goren, et al.
Investigational New Drugs|January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patientsAlberto A Gabizon, Esther Tahover, Talia Golan, et al.
Bioconjugate Chemistry|March 17, 1999
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studiesA Gabizon, A T Horowitz, D Goren, et al.
Seminars in Oncology|February 19, 2005
Cardiac safety of liposomal anthracyclinesMichael S Ewer, Francis J Martin, Craig Henderson, et al.
Cancer Research|February 15, 1994
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesA Gabizon, R Catane, B Uziely, et al.
Cancer|August 30, 2000
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaO Lyass, B Uziely, R Ben-Yosef, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 10, 2014
Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responsesManoj K Sabnani, Robin Rajan, Bradley Rowland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studiesB Uziely, S Jeffers, R Isacson, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyA Gabizon, T Peretz, A Sulkes, et al.
British Journal of Cancer|December 1, 1991
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycinA Gabizon, R Chisin, S Amselem, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Medicinal Research Reviews|July 1, 1993
Stability of liposomal doxorubicin formulations: problems and prospectsY Barenholz, S Amselem, D Goren, et al.
Investigational New Drugs|January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patientsAlberto A Gabizon, Esther Tahover, Talia Golan, et al.
Bioconjugate Chemistry|March 17, 1999
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studiesA Gabizon, A T Horowitz, D Goren, et al.
Seminars in Oncology|February 19, 2005
Cardiac safety of liposomal anthracyclinesMichael S Ewer, Francis J Martin, Craig Henderson, et al.
Cancer Research|February 15, 1994
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesA Gabizon, R Catane, B Uziely, et al.
Cancer|August 30, 2000
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaO Lyass, B Uziely, R Ben-Yosef, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 10, 2014
Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responsesManoj K Sabnani, Robin Rajan, Bradley Rowland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studiesB Uziely, S Jeffers, R Isacson, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyA Gabizon, T Peretz, A Sulkes, et al.
British Journal of Cancer|December 1, 1991
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycinA Gabizon, R Chisin, S Amselem, et al.
Pageof 9